CN109420053A - A kind of pharmaceutical composition for treating fatty liver - Google Patents
A kind of pharmaceutical composition for treating fatty liver Download PDFInfo
- Publication number
- CN109420053A CN109420053A CN201710749205.3A CN201710749205A CN109420053A CN 109420053 A CN109420053 A CN 109420053A CN 201710749205 A CN201710749205 A CN 201710749205A CN 109420053 A CN109420053 A CN 109420053A
- Authority
- CN
- China
- Prior art keywords
- parts
- rhizoma
- pharmaceutical composition
- taenian
- bezoar
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000010706 fatty liver disease Diseases 0.000 title claims abstract description 27
- 208000004930 Fatty Liver Diseases 0.000 title claims abstract description 26
- 206010019708 Hepatic steatosis Diseases 0.000 title claims abstract description 26
- 231100000240 steatosis hepatitis Toxicity 0.000 title claims abstract description 26
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 206010004542 Bezoar Diseases 0.000 claims abstract description 24
- 235000001287 Guettarda speciosa Nutrition 0.000 claims abstract description 16
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- 239000012141 concentrate Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 241000125175 Angelica Species 0.000 claims description 15
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 14
- 239000012153 distilled water Substances 0.000 claims description 14
- 238000001035 drying Methods 0.000 claims description 14
- 235000019441 ethanol Nutrition 0.000 claims description 14
- 239000000706 filtrate Substances 0.000 claims description 14
- 239000000463 material Substances 0.000 claims description 9
- 239000004375 Dextrin Substances 0.000 claims description 7
- 229920001353 Dextrin Polymers 0.000 claims description 7
- 239000004471 Glycine Substances 0.000 claims description 7
- 235000019425 dextrin Nutrition 0.000 claims description 7
- 239000003814 drug Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000010438 heat treatment Methods 0.000 claims description 7
- 239000000843 powder Substances 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 6
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 5
- 229930195725 Mannitol Natural products 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 5
- 239000000594 mannitol Substances 0.000 claims description 5
- 235000010355 mannitol Nutrition 0.000 claims description 5
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000002552 dosage form Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 5
- 244000061520 Angelica archangelica Species 0.000 abstract 1
- 210000004185 liver Anatomy 0.000 description 6
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 210000001015 abdomen Anatomy 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000002440 hepatic effect Effects 0.000 description 2
- 208000007743 Acute Abdomen Diseases 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 206010014418 Electrolyte imbalance Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010019799 Hepatitis viral Diseases 0.000 description 1
- 206010029240 Neuritis Diseases 0.000 description 1
- 206010030124 Oedema peripheral Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 208000034158 bleeding Diseases 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 208000001780 epistaxis Diseases 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 238000002350 laparotomy Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/37—Digestive system
- A61K35/413—Gall bladder; Bile
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/84—Valerianaceae (Valerian family), e.g. valerian
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8964—Anemarrhena
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a kind of pharmaceutical compositions for treating fatty liver, mainly as made by the raw material of following parts by weight: 40-58 parts of ramulus cinnamomi, 35-55 parts of the root of Dahurain angelica, 25-45 parts of rhizoma anemarrhenae, 10-18 parts of cow-bezoar, 10-15 parts of caulis bambusae in taenian, 4-8 parts of rhizoma nardostachyos, 4-6 parts of Rhizoma Atractylodis Macrocephalae；Compared with prior art, the pharmaceutical composition can effectively treat fatty liver, and at low cost, Small side effects, can be adapted for the elderly with fatty liver, preparation method is simple simultaneously, saves artificial and cost, can utilize raw material to greatest extent, improves bioavilability.
Description
Technical field
The present invention relates to a kind of pharmaceutical compositions, and in particular to a kind of pharmaceutical composition for treating fatty liver.
Background technique
Fatty liver refers to the lesion that fat accumulation is excessive in caused liver cell due to various reasons.Fatty liver disease is just
The health for seriously threatening compatriots becomes the second largest hepatopathy for being only second to virus hepatitis.Fatty liver is that a kind of common clinic is existing
As, rather than a kind of independent disease.Its clinical manifestation less serious case is asymptomatic, and the severe one state of an illness is violent.In general, fatty liver belongs to reversible
Property disease, early diagnose and treat can often restore normal in time.The diverse clinical manifestations of fatty liver, mild fatty liver is mostly without clinic
Symptom.Only tired sense, and most Patients with Fatty Liver are more fat.Fatty liver patient chances on when being more than physical examination.In, severe fat
Liver has the performance of similar chronic hepatitis, can there is loss of appetite, lassitude and weak, Nausea and vomiting, hepatic region or upper right abdomen secret anguish etc..Liver
Dirty silght enlargement can have tenderness, and quality is slightly tough, edge is blunt, surface is smooth, and a few patients can have splenomegaly and liver palms.When liver lactones
When fat deposition is excessive, liver can be made to be pulled by membrane swelling, hepatic ligament, and cause the severe pain of upper right abdomen or tenderness, fever, leucocyte
Counting increases, and mistaken diagnosis makees laparotomy ventrotomy for acute abdomen.In addition, fatty liver patient also often have glossitis, angular stomatitis, skin ecchymosis,
The change of the peripheral neuritis such as numb limb, meropresthesia.A few patients can also have hemorrhage of digestive tract, bleeding gums, nose
Nosebleed etc..Severe fatty liver patient can have seroperitoneum and edema of lower extremity, electrolyte disturbance such as low sodium and low potassium mass formed by blood stasis etc., fat
Liver performance multiplicity, when meeting difficult diagnosis, can do liver biopsy and make a definite diagnosis.The most single effect of drug, valuableness, secondary work currently on the market
With obvious, the elderly with fatty liver is not suitable for, so being badly in need of researching and developing a kind of good effect, at low cost, secondary work
With the compound medicine of small treatment fatty liver.
Summary of the invention
Summary of the invention: in view of the deficienciess of the prior art, the present invention provides a kind of pharmaceutical composition for treating fatty liver,
The pharmaceutical composition can treat fatty liver, and at low cost, Small side effects well, can be adapted for the old age with fatty liver
People.
Technical solution: to achieve the goals above, a kind of pharmaceutical composition for treating fatty liver as described herein, mainly
As made by the raw material of following parts by weight: 40-58 parts of ramulus cinnamomi, 35-55 parts of the root of Dahurain angelica, 25-45 parts of rhizoma anemarrhenae, 10-18 parts of cow-bezoar, caulis bambusae in taenian
10-15 parts, 4-8 parts of rhizoma nardostachyos, 4-6 parts of Rhizoma Atractylodis Macrocephalae.
Further, the pharmaceutical composition, mainly as made by the raw material of following parts by weight: 45-50 parts of ramulus cinnamomi, white
40-50 parts of the root of Dahurian angelica, 30-40 parts of rhizoma anemarrhenae, 15-18 parts of cow-bezoar, 12-15 parts of caulis bambusae in taenian, 6-8 parts of rhizoma nardostachyos, 5-6 parts of Rhizoma Atractylodis Macrocephalae.
Further, the preparation method of described pharmaceutical composition, includes the following steps:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 120-150 mesh, used
Water immersion powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, and cross 60-80 mesh, cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, white is added
The distilled water heating of 2-4 times of art total weight is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, volume fraction 70-80% ethyl alcohol is added and impregnates 2-4 hours, is all waved to ethyl alcohol
After hair, distilled water is added and mixes, concentrate C is obtained after concentrate drying；
(4) clinical required finished dosage forms are made in the auxiliary material for adding concentrate C.
Further, step (4) auxiliary material be one of sodium carboxymethylcellulose, dextrin, glycine, mannitol or
Several combinations.
Further, step (4) dosage form is tablet, liquid drugs injection or capsule.
The utility model has the advantages that being compared by the prior art, the pharmaceutical composition for the treatment of fatty liver of the invention has the advantages that one
The pharmaceutical composition of kind treatment fatty liver, the pharmaceutical composition can effectively treat fatty liver, and at low cost, Small side effects,
It can be adapted for the elderly with treatment fatty liver, while preparation method is simple, save artificial and cost, can be to greatest extent
Utilize raw material, improve bioavilability.
Specific embodiment
Embodiment 1
Prescription:
40 parts of ramulus cinnamomi, 35 parts of the root of Dahurain angelica, 25 parts of rhizoma anemarrhenae, 10 parts of cow-bezoar, 10 parts of caulis bambusae in taenian, 4 parts of rhizoma nardostachyos, 4 parts of Rhizoma Atractylodis Macrocephalae.
Preparation method:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 120 meshes, use water logging
No powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, cross 60 meshes, it is total that cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae is added
The distilled water heating that 2 times of weight is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, 70% ethyl alcohol of volume fraction is added and impregnates 4 hours, after ethyl alcohol all volatilization,
Distilled water is added to mix, concentrate C is obtained after concentrate drying；
(4) auxiliary material sodium carboxymethylcellulose, dextrin, the glycine for adding concentrate C, is made tablet.
Embodiment 2
Prescription:
58 parts of ramulus cinnamomi, 55 parts of the root of Dahurain angelica, 45 parts of rhizoma anemarrhenae, 18 parts of cow-bezoar, 15 parts of caulis bambusae in taenian, 8 parts of rhizoma nardostachyos, 6 parts of Rhizoma Atractylodis Macrocephalae.
Preparation method:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 150 meshes, use water logging
No powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, cross 80 meshes, it is total that cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae is added
The distilled water heating that 4 times of weight is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, 80% ethyl alcohol of volume fraction is added and impregnates 4 hours, after ethyl alcohol all volatilization,
Distilled water is added to mix, concentrate C is obtained after concentrate drying；
(4) auxiliary material sodium carboxymethylcellulose, dextrin, the glycine for adding concentrate C, is made tablet.
Embodiment 3
Prescription:
50 parts of ramulus cinnamomi, 45 parts of the root of Dahurain angelica, 32 parts of rhizoma anemarrhenae, 15 parts of cow-bezoar, 13 parts of caulis bambusae in taenian, 6 parts of rhizoma nardostachyos, 5 parts of Rhizoma Atractylodis Macrocephalae.
Preparation method:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 135 meshes, use water logging
No powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, cross 70 meshes, it is total that cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae is added
The distilled water heating that 3 times of weight is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, 75% ethyl alcohol of volume fraction is added and impregnates 3 hours, after ethyl alcohol all volatilization,
Distilled water is added to mix, concentrate C is obtained after concentrate drying；
(4) auxiliary material mannitol, dextrin, the glycine for adding concentrate C, is made liquid drugs injection.
Embodiment 4
Prescription:
45 parts of ramulus cinnamomi, 40 parts of the root of Dahurain angelica, 30 parts of rhizoma anemarrhenae, 15 parts of cow-bezoar, 12 parts of caulis bambusae in taenian, 6 parts of rhizoma nardostachyos, 5 parts of Rhizoma Atractylodis Macrocephalae.
Preparation method:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 135 meshes, use water logging
No powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, cross 70 meshes, it is total that cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae is added
The distilled water heating that 3 times of weight is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, 75% ethyl alcohol of volume fraction is added and impregnates 3 hours, after ethyl alcohol all volatilization,
Distilled water is added to mix, concentrate C is obtained after concentrate drying；
(4) auxiliary material mannitol, dextrin, the glycine for adding concentrate C, is made liquid drugs injection.
Embodiment 5
Prescription:
50 parts of ramulus cinnamomi, 50 parts of the root of Dahurain angelica, 40 parts of rhizoma anemarrhenae, 18 parts of cow-bezoar, 15 parts of caulis bambusae in taenian, 8 parts of rhizoma nardostachyos, 6 parts of Rhizoma Atractylodis Macrocephalae.
Preparation method:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 135 meshes, use water logging
No powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, cross 70 meshes, it is total that cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae is added
The distilled water heating that 3 times of weight is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, 75% ethyl alcohol of volume fraction is added and impregnates 3 hours, after ethyl alcohol all volatilization,
Distilled water is added to mix, concentrate C is obtained after concentrate drying；
(4) auxiliary material mannitol, dextrin, the glycine for adding concentrate C, is made liquid drugs injection.
Claims (5)
1. a kind of pharmaceutical composition for treating fatty liver, which is characterized in that mainly as made by the raw material of following parts by weight: ramulus cinnamomi
40-58 parts, 35-55 parts of the root of Dahurain angelica, 25-45 parts of rhizoma anemarrhenae, 10-18 parts of cow-bezoar, 10-15 parts of caulis bambusae in taenian, 4-8 parts of rhizoma nardostachyos, 4-6 parts of Rhizoma Atractylodis Macrocephalae.
2. pharmaceutical composition according to claim 1, which is characterized in that mainly as made by the raw material of following parts by weight:
45-50 parts of ramulus cinnamomi, 40-50 parts of the root of Dahurain angelica, 30-40 parts of rhizoma anemarrhenae, 15-18 parts of cow-bezoar, 12-15 parts of caulis bambusae in taenian, 6-8 parts of rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae 5-6
Part.
3. pharmaceutical composition according to claim 1, which is characterized in that the preparation method of described pharmaceutical composition, including
Following steps:
(1) above-mentioned raw materials are weighed by recipe ratio, dry ramulus cinnamomi, the root of Dahurain angelica, rhizoma anemarrhenae is crushed into 120-150 mesh, use water logging
No powder, with being cooked by slow fire, collecting decoction filtering obtains filtrate A；
(2) it will be ground after cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae drying, cross 60-80 mesh, it is total that cow-bezoar, caulis bambusae in taenian, rhizoma nardostachyos, Rhizoma Atractylodis Macrocephalae is added
2-4 times of weight of distilled water heating is boiled, cooled and filtered, and liquor B is spare；
(3) filtrate A and liquor B are mixed, volume fraction 70-80% ethyl alcohol is added and impregnates 2-4 hours, all volatilized to ethyl alcohol
Afterwards, distilled water is added to mix, concentrate C is obtained after concentrate drying；
(4) clinical required finished dosage forms are made in the auxiliary material for adding concentrate C.
4. pharmaceutical composition according to claim 3, which is characterized in that step (4) auxiliary material is carboxymethyl cellulose
The combination of one or more of sodium dextrin, glycine, mannitol.
5. pharmaceutical composition according to claim 3, which is characterized in that step (4) dosage form be tablet, liquid drugs injection or
Capsule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710749205.3A CN109420053A (en) | 2017-08-28 | 2017-08-28 | A kind of pharmaceutical composition for treating fatty liver |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710749205.3A CN109420053A (en) | 2017-08-28 | 2017-08-28 | A kind of pharmaceutical composition for treating fatty liver |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109420053A true CN109420053A (en) | 2019-03-05 |
Family
ID=65502460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710749205.3A Pending CN109420053A (en) | 2017-08-28 | 2017-08-28 | A kind of pharmaceutical composition for treating fatty liver |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109420053A (en) |
-
2017
- 2017-08-28 CN CN201710749205.3A patent/CN109420053A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103520572A (en) | Traditional Chinese composition used for treating atopic dermatitis as well as preparation method of composition | |
| CN103223118B (en) | Traditional Chinese medicine composition for treating facial paralysis | |
| CN104940810A (en) | Traditional Chinese medicine composition for treating angina | |
| CN104587381A (en) | Traditional Chinese medicine preparation for treating chronic cholecystitis | |
| CN103272105B (en) | Tablet for treating diabetic nephropathy | |
| CN102293969B (en) | Chinese medicine for treating fatty liver | |
| CN104857188A (en) | Traditional Chinese medicine composite for treating edema | |
| CN109420053A (en) | A kind of pharmaceutical composition for treating fatty liver | |
| CN102920862A (en) | Chinese medicinal composition for treating ascites due to cirrhosis | |
| CN109420055A (en) | A kind of preparation method of pharmaceutical composition that treating fatty liver | |
| CN103251901B (en) | Oral traditional Chinese medicine preparation for treating dysmenorrhea | |
| CN102114211B (en) | Chinese herbal medicine for treating hepatopathy | |
| CN105456924A (en) | Traditional Chinese medicine preparation containing Folium Artemisiae Argyi and having functions of promoting circulation and removing stasis and preparation method thereof | |
| CN105381289A (en) | Pharmaceutical composition for treating abnormal menstruation | |
| CN104510972A (en) | Traditional Chinese medicinal composition for treating asthma and preparation method of traditional Chinese medicinal composition | |
| CN1326555C (en) | Chinese medicinal powder preparation for treating hepatic ascites | |
| CN104147219A (en) | Traditional Chinese medicine composition for easing pain and dizziness and preparation method of traditional Chinese medicine composition | |
| CN104225344A (en) | Chinese herbal preparation for treating chronic nephropyelitis and preparation method thereof | |
| CN103933269A (en) | Traditional Chinese medicine for treating metrorrhagia disease | |
| CN103800736A (en) | Pharmaceutical composition for treating hypertensive nephrosclerosis and application of pharmaceutical composition | |
| CN103446410B (en) | Traditional Chinese medicine preparation for treating viral myocarditis | |
| CN103263562A (en) | Traditional Chinese medicine for treating Qi deficiency type constipation | |
| CN108704064A (en) | A kind of Chinese medicine composition and preparation method for treating AIDS | |
| CN105582245A (en) | Preparation for preventing and treating nephritic syndrome and preparation method of preparation | |
| CN104056196A (en) | Traditional Chinese medicine composition for treating bradycardia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190305 |
|
| WD01 | Invention patent application deemed withdrawn after publication |